Rep. Sara Feigenholtz

Filed: 3/26/2014

 

 


 

 


 
09800HB3956ham001LRB098 15516 ZMM 57504 a

1
AMENDMENT TO HOUSE BILL 3956

2    AMENDMENT NO. ______. Amend House Bill 3956 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Pharmacy Practice Act is amended by adding
5Section 25.25 as follows:
 
6    (225 ILCS 85/25.25 new)
7    Sec. 25.25. Opioid analgesic drugs.
8    (a) For the purposes of this Section:
9    "Interchange or substitution of an opioid analgesic drug"
10means the substitution of any brand name or generic opioid
11analgesic drug for a prescribed opioid analgesic drug
12incorporating a tamper-resistance technology, whether or not
13the substituted drug is rated as pharmaceutically and
14therapeutically equivalent by the United States Food and Drug
15Administration or the Board or whether the opioid analgesic
16drug with tamper-resistance technology bears a labeling claim

 

 

09800HB3956ham001- 2 -LRB098 15516 ZMM 57504 a

1with respect to reduction of tampering, abuse, or abuse
2potential.
3    "Opioid analgesic drug" means a drug in the opioid drug
4class prescribed to treat moderate to severe pain or other
5conditions, including opioid dependence, whether in immediate
6release or extended release form and whether or not combined
7with other drug substances to form a single tablet or other
8dosage form.
9    "Opioid analgesic drug incorporating a tamper-resistance
10technology" means an opioid analgesic drug listed as such by
11the Board under subsection (b).
12    (b) The Board shall establish a list of the opioid
13analgesic drugs for which it has received evidence from the
14drug manufacturer or distributor that the drug incorporates a
15tamper-resistance technology.
16    The list shall also include a determination by the Board as
17to which of the opioid analgesic drugs incorporating
18tamper-resistance technologies on the list provide
19substantially similar tamper-resistance properties. Such a
20determination by the Board shall be based solely on any studies
21submitted to the United States Food and Drug Administration
22with the drug manufacturer's application for approval.
23    (c) The Board shall not exclude an opioid analgesic drug
24from the list established under subsection (b) on the basis
25that the drug does not bear a labeling claim with respect to
26reduction of tampering, abuse, or abuse potential at the time

 

 

09800HB3956ham001- 3 -LRB098 15516 ZMM 57504 a

1the drug is being considered for placement on the list or any
2time after the drug's placement on the list.
3    (d) A pharmacist shall not interchange or substitute a
4brand name or generic opioid analgesic drug otherwise eligible
5for interchange or substitution under this Section without
6doing one of the following:
7        (1) verifying that the Board has determined under
8    subsection (b) that the opioid analgesic drug provides
9    tamper-resistance properties substantially similar to the
10    prescribed opioid analgesic drug incorporating a
11    tamper-resistance technology; or
12        (2) obtaining written, signed consent from the
13    prescriber for the interchange or substitution.
 
14    Section 99. Effective date. This Act takes effect January
151, 2015.".